Chanock R M, Crowe J E, Murphy B R, Burton D R
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Infect Agents Dis. 1993 Jun;2(3):118-31.
Currently, there is increased interest in the use of human viral antibodies for prophylaxis and therapy because recent advances in molecular immunology have made it possible to generate large numbers of human monoclonal antibodies of desired specificity and functional activity in short order. The strategy, developed particularly at The Scripps Research Institute and at Cambridge University is based on antigen selection of such antibodies from combinatorial libraries that express Fabs on the surface of filamentous DNA bacteriophage. Fabs or their whole immunoglobulin derivatives that exhibit high avidity for the selecting antigen and high neutralizing activity for the corresponding virus have been identified, and many of these human monoclonal antibodies should prove to be useful in prophylaxis or therapy of presently uncontrolled, medically important human viral diseases.
目前，人们对使用人类病毒抗体进行预防和治疗的兴趣日益浓厚，因为分子免疫学的最新进展使得在短时间内产生大量具有所需特异性和功能活性的人类单克隆抗体成为可能。特别是由斯克里普斯研究所和剑桥大学开发的策略，是基于从丝状DNA噬菌体表面表达Fabs的组合文库中选择此类抗体的抗原。已经鉴定出对选择抗原具有高亲和力且对相应病毒具有高中和活性的Fabs或其完整免疫球蛋白衍生物，并且这些人类单克隆抗体中的许多应该被证明可用于预防或治疗目前无法控制的、具有医学重要性的人类病毒性疾病。
